Comparative Pharmacology
Head-to-head clinical analysis: ACULAR versus ACULAR LS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACULAR versus ACULAR LS.
ACULAR vs ACULAR LS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Selective COX-2 inhibitor; inhibits prostaglandin synthesis, reducing ocular inflammation and pain.
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
1 drop in the affected eye(s) four times daily
None Documented
None Documented
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
The terminal elimination half-life is approximately 1.8 hours (range 1.2–2.5 hours) following topical ocular administration. This short half-life is consistent with rapid clearance from the systemic circulation.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
Renal excretion of metabolites and unchanged drug accounts for approximately 26% of the dose. Fecal excretion accounts for approximately 74% of the dose, primarily as metabolites.
Category C
Category C
NSAID Ophthalmic
NSAID Ophthalmic